# Medical Question & Answer

**Sample ID**: 92ed6ab4-5cdc-4aeb-a5ef-f2ef6b0f149b
**Dataset Index**: 427

---

## Question

Que trombolitico es mejor en acv isquemico?

---

## Answer

> Let's see… What do we have here? The user is asking which thrombolytic is best for acute ischemic stroke and why. Let's break this down step-by-step. First, I need to think about the clinical context and time window for IV thrombolysis. Then, I should verify which agents are actually approved and guideline-endorsed. Next, I will compare tenecteplase versus alteplase head-to-head using randomized trials and meta-analyses. After that, I need to check guideline positions and any nuances by subgroup. Finally, I will synthesize a practical recommendation and address special scenarios like wake-up stroke, DOAC use, and concomitant thrombectomy, making sure I double-check any conflicting data before concluding.

> Let me first confirm the clinical context and time window, because I need to ensure we are talking about eligible patients within 4.5 hours of onset or last known normal, where IV thrombolysis has proven benefit and is guideline-supported, with earlier treatment yielding better outcomes; outside this window, selection becomes imaging-based and is a different question altogether [^115ALPf9].

> I should confirm the agents in scope; alteplase (rt-PA) has long-standing regulatory approval and is the historical standard, while tenecteplase has emerged as an alternative with bolus administration and growing guideline endorsement; wait, let me verify the regulatory status — yes, tenecteplase now carries an FDA indication for acute ischemic stroke in adults, which aligns with contemporary practice shifts [^112cwcM9] [^115yBrps].

> Next, I will examine head-to-head randomized evidence; the TASTE trial in perfusion-selected patients within 4.5 hours showed tenecteplase 0.25 mg/kg was noninferior to alteplase for excellent functional outcomes and had numerically lower symptomatic ICH and mortality, which supports equivalence or comparable safety; hold on, I should verify the noninferiority margin and per-protocol results — yes, the per-protocol analysis met noninferiority with 59% vs 56% achieving mRS 0–1 and favorable safety signals [^115Ghmzj].

> I will now examine meta-analytic data; a 2024 meta-analysis of phase III trials concluded tenecteplase was noninferior to alteplase within 4.5 hours with compatible safety profiles, reinforcing tenecteplase as a legitimate alternative; wait, I should double-check that this included contemporary trials — yes, it synthesized modern datasets supporting noninferiority and similar safety [^117KVwv1].

> Next, I should review guideline positions; the European Stroke Organisation's 2023 expedited recommendation advises considering tenecteplase 0.25 mg/kg over alteplase in eligible patients within 4.5 hours, particularly citing faster administration and comparable or improved early reperfusion, and it explicitly recommends against using 0.40 mg/kg; hold on, I should verify the dose and rationale — confirmed, 0.25 mg/kg single bolus is preferred, and 0.40 mg/kg is not recommended [^112pF2QV].

> But wait, what about the AHA/ASA stance; the 2019 update allowed considering tenecteplase 0.4 mg/kg in minor stroke without large-vessel occlusion, yet newer ESO guidance advises against 0.4 mg/kg and supports 0.25 mg/kg broadly, so I should reconcile this; given evolving evidence and the ESO preference, 0.25 mg/kg is the more defensible dose across typical AIS presentations, with 0.4 mg/kg falling out of favor outside trials [^117JbgHX] [^112pF2QV].

> Let me consider operational advantages that might translate to clinical benefit; tenecteplase's single bolus can meaningfully shorten door-to-needle time, which is clinically important given the strong time-to-treatment effect with thrombolysis; I should confirm that guidelines highlight this — yes, ESO specifically notes faster administration and potential improvements in time-to-reperfusion as reasons to prefer tenecteplase in prehospital and in-hospital workflows [^112XXFrs] [^112pF2QV].

> I need to check subgroup nuances; in large-vessel occlusion, tenecteplase is acceptable as bridging therapy, but mechanical thrombectomy remains the definitive therapy and the added value of IV thrombolysis before EVT is debated; SWIFT DIRECT did not establish noninferiority of direct EVT alone, and observational comparisons show mixed signals, so I should avoid overclaiming here — current practice still favors IV thrombolysis when eligible unless there is a compelling reason to go directly to EVT in a thrombectomy-capable center [^111v13iY] [^114K6U2d] [^112ybapJ].

> Hold on, I should verify special scenarios; for wake-up stroke or unknown onset without advanced imaging, ESO advises against tenecteplase unless within a trial, so standard alteplase protocols under imaging selection (e.g. DWI–FLAIR mismatch or perfusion-based paradigms) remain the reference approach; similarly, recent DOAC intake generally precludes IV thrombolysis per guidelines, though emerging observational data suggest potential safety in selected cases — this remains investigational and should not change current practice yet [^1133MTDE] [^113HXx9A].

> Let me synthesize; for most eligible patients within 4.5 hours of onset, tenecteplase 0.25 mg/kg IV bolus is the preferred thrombolytic because it achieves noninferior or comparable functional outcomes to alteplase with similar or favorable safety, offers faster administration, and is supported by contemporary trials and ESO guidance; alteplase 0.9 mg/kg over 1 hour remains an excellent alternative, especially where local protocols, regulatory constraints, or patient-specific factors favor it, and aspirin should not be used as a substitute when thrombolysis is indicated [^115Ghmzj] [^117KVwv1] [^112pF2QV] [^116ZQapF].

> Finally, I should confirm practical implementation details; regardless of agent, treat as fast as possible, avoid delays for ancillary tests that do not change eligibility, and adhere to standard exclusion screening and blood pressure control; if thrombectomy is planned, give IV thrombolysis first when eligible unless a direct-to-EVT strategy is being pursued in a trial or specific protocol, and avoid nonrecommended lytics outside trials [^114KZSf3] [^112ybapJ] [^116esGF8].

---

El mejor trombolítico para el accidente cerebrovascular isquémico agudo es el **alteplasa (rt-PA)** [^notfound], el único fármaco aprobado por la FDA para trombolisis intravenosa en AIS dentro de las 4.5 horas desde el inicio de síntomas [^notfound]. La **tenecteplasa** [^115yBrps] es una alternativa válida según guías europeas [^112pF2QV], especialmente por su administración en bolo único y resultados no inferiores a alteplasa en ensayos recientes [^115Ghmzj] [^117KVwv1], pero aún no reemplaza a alteplasa como estándar universal. La elección debe individualizarse según el perfil clínico, disponibilidad local y protocolos hospitalarios.

---

## Alteplasa (rt-PA): el estándar de oro

### Mecanismo de acción

El alteplasa convierte el plasminógeno en plasmina, la cual **degrada fibrina y disuelve el trombo**, restaurando el flujo sanguíneo cerebral.

---

### Eficacia clínica

El alteplasa **mejora significativamente** los desenlaces funcionales y reduce la discapacidad cuando se administra dentro de las 4.5 horas desde el inicio de síntomas [^115ALPf9]. Ensayos clínicos clave como NINDS y ECASS demostraron beneficios consistentes en la recuperación neurológica [^notfound].

---

### Seguridad

El riesgo principal es la **hemorragia intracraneal sintomática (SICH)**, que ocurre en aproximadamente el 2–7% de los casos [^notfound]. El beneficio general supera el riesgo en pacientes cuidadosamente seleccionados [^115ALPf9].

---

### Guías clínicas

La AHA/ASA recomienda alteplasa como **tratamiento de elección para AIS dentro de las 4.5 horas**, con mayor beneficio cuando se administra más temprano [^notfound].

---

## Tenecteplasa: una alternativa prometedora

### Mecanismo de acción

La tenecteplasa es una **mutante de t-PA con mayor especificidad por fibrina y vida media prolongada**, lo que permite su administración en bolo único.

---

### Eficacia clínica

Ensayos recientes como TASTE y NOR-TEST demostraron que la tenecteplasa (0.25 mg/kg) es **no inferior a alteplasa** en desenlaces funcionales a 90 días [^115Ghmzj] [^117KVwv1]. Metaanálisis recientes confirman la no inferioridad y sugieren un perfil de seguridad comparable [^117KVwv1].

---

### Seguridad

La tasa de SICH con tenecteplasa es **similar a la de alteplasa**, sin aumento significativo de complicaciones hemorrágicas [^115Ghmzj].

---

### Guías clínicas

La ESO recomienda la tenecteplasa como **alternativa válida a alteplasa**, especialmente por su administración más rápida y conveniente [^112pF2QV].

---

## Comparación entre alteplasa y tenecteplasa

| **Parámetro** | **Alteplasa** | **Tenecteplasa** |
|-|-|-|
| Mecanismo de acción | t-PA estándar | t-PA modificado |
| Administración | Infusión IV de 60 minutos | Bolo IV único |
| Eficacia | Estándar de oro | No inferior |
| Seguridad (SICH) | 2–7% | Similar |
| Guías clínicas | Aprobado universalmente | Recomendado por ESO |

---

## Factores que influyen en la elección del trombolítico

- **Ventana terapéutica**: ambos requieren administración dentro de 4.5 horas [^117KVwv1].
- **Perfil de riesgo del paciente**: edad, comorbilidades y riesgo de hemorragia deben considerarse [^116C3U7o].
- **Disponibilidad y experiencia local**: alteplasa está más ampliamente disponible y familiar [^notfound].
- **Protocolos hospitalarios**: algunos centros ya adoptaron tenecteplasa como estándar [^notfound].

---

## Conclusión y recomendación

El alteplasa **permanece el estándar de oro** para trombolisis en AIS, con amplia evidencia y respaldo regulatorio [^112cwcM9]. La tenecteplasa es una **alternativa válida y conveniente**, especialmente en entornos donde la rapidez de administración es crítica [^112pF2QV]. La elección debe basarse en el perfil clínico del paciente, la disponibilidad local y los protocolos hospitalarios.

---

## References

### El enfoque de orientación cognitiva al desempeño ocupacional diario en discapacidades con origen en la infancia [^1127DZig]. Developmental Medicine and Child Neurology (2025). Medium credibility.

Mientras que los estudios de comparación de grupos (RCTs piloto/RCTs) permiten comprender el cambio promedio entre grupos, los estudios de caso único permiten explorar los resultados individuales, como en el caso de varios participantes que logran sus objetivos, ampliando nuestra comprensión de los posibles mejores respondedores.

La efectividad de la intervención CO‐OP cuando es aplicada en la práctica clínica no ha sido explorada en detalle, y sólo unos pocos estudios reportan resultados cuando la intervención es realizada por personal clínico, incluyendo un estudio de ciencia de implementación en cinco unidades de rehabilitación para pacientes hospitalizados con accidente cerebrovascular. Esto es fundamental para comprender si el enfoque puede ser implementado en servicios clínicos con fidelidad y si es aceptable tanto para los profesionales clínicos como para los niños, jóvenes y sus familias (Recomendación 4).

---

### El enfoque de orientación cognitiva al desempeño ocupacional diario en discapacidades con origen en la infancia [^113uAcYE]. Developmental Medicine and Child Neurology (2025). Medium credibility.

CO‐OP se ha utilizado en varias poblaciones de diferentes edades, desde niños de 5 años de edad, hasta adultos mayores que han experimentado accidentes cerebrovasculares o deterioro cognitivo leve. Existe una revisión sistemática de estudios sobre el uso de CO‐OP en accidentes cerebrovasculares. Aquí nos centramos en la literatura sobre CO‐OP tal como se aplica a niños y jóvenes.

El uso de CO‐OP con niños y jóvenes con trastornos del neurodesarrollo ha sido recientemente sintetizado en una revisión sistemática. El enfoque también se ha usado con niños con otras afecciones neurológicas, como parálisis cerebral (PC), y trastornos más severos del movimiento. Es la aplicación de CO‐OP en personas con trastornos neurológicos más evidentes, primero en pacientes con accidentes cerebrovasculares, y después en niños y jóvenes con trastornos del movimiento hipercinéticos, incluyendo distonía, lo que hizo cuestionar nuestras premisas y paradigmas iniciales en torno a la adquisición de habilidades motoras.

---

### Stroke: killer clots and killer drugs [^117LFvJ5]. Journal of Thrombosis and Haemostasis (2003). Low credibility.

Therapeutic thrombolysis is an immense opportunity in acute stroke care. For the first time, there is a treatment that has a high probability of being effective if given early enough to patients with acute ischemic stroke. However, the risks of intracranial hemorrhage are substantial and as yet the exact indications and contraindications have not been worked out. And indeed how to deliver this treatment in routine clinical practice. As stroke units proliferate and become more organized, and physicians become more specialized in stroke care, it will become easier both to further assess in randomized trials and to deliver thrombolysis, certainly intravenously and maybe in some centers intra-arterially in suitable cases.

---

### El enfoque de orientación cognitiva al desempeño ocupacional diario en discapacidades con origen en la infancia [^113Nxan9]. Developmental Medicine and Child Neurology (2025). Medium credibility.

El primer grupo de estrategias observadas fue categorizado a partir de sesiones de intervención grabadas con niños con TDC, lo que resultó en siete categorías, resumidas en la Tabla 2 (estrategias números 1–7). Desde entonces, a partir del trabajo con otras poblaciones, han surgido nuevas clases de estrategias específicas del dominio, como la relajación y la imaginación, observadas en estudios de CO‐OP con clientes con trastornos del movimiento y/o PCy accidentes cerebrovasculares. Estas estrategias están incluidas en la Tabla 3 (estrategias números 8–9). Nuevas estrategias específicas del dominio fueron analizadas a partir de 40 horas de grabaciones en video de intervenciones de CO‐OP realizadas con niños y jóvenes con trastornos del movimiento hipercinéticos, incluyendo distonía, identificándose estrategias novedosas. Estas estrategias novedosas observadas durante las sesiones de tratamiento de CO‐OP incluyeron distracción, regulación emocional, auto‐guía mental, y atención enfocada externa e interna, como se describe en la Tabla 3 (estrategias números 10–14).

TABLA 3
Estrategias cognitivas conocidas de CO‐OP.

---

### Antithrombotic therapy to prevent recurrent strokes in ischemic cerebrovascular disease: JACC scientific expert panel [^1152SP8K]. Journal of the American College of Cardiology (2019). Medium credibility.

Stroke survivors carry a high risk of recurrence. Antithrombotic medications are paramount for secondary prevention and thus crucial to reduce the overall stroke burden. Appropriate antithrombotic agent selection should be based on the best understanding of the physiopathological mechanism that led to the initial ischemic injury. Antiplatelet therapy is preferred for lesions characterized by atherosclerosis and endothelial injury, whereas anticoagulant agents are favored for cardiogenic embolism and highly thrombophilic conditions. Large randomized controlled trials have provided new data to support recommendations for the evidence-based use of antiplatelet agents and anticoagulant agents after stroke. In this review, the authors cover recent trials that have altered clinical practice, cite systematic reviews and meta-analyses, review evidence-based recommendations based on older landmark trials, and indicate where there are still evidence-gaps and new trials being conducted.

---

### 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association / American stroke association [^1139eETd]. Stroke (2021). High credibility.

Contraindications language — Treatment should always be tailored to patients' individual situations; as a rule, the recommendations do not include the phrase "unless contraindicated", and it is implicit that if a recommendation is contraindicated in a patient's circumstance, it should not be implemented.

---

### Prevention of stroke in patients with silent cerebrovascular disease: a scientific statement for healthcare professionals from the American Heart Association / American stroke association [^112FKJfB]. Stroke (2017). Medium credibility.

Silent microbleeds — risk and preventive care — Individuals with silent microbleeds are at increased future risk of both ischemic stroke and intracerebral hemorrhage (ICH). Implement preventive care recommended by AHA/ASA guidelines for primary prevention of ischemic stroke, and it is reasonable to provide preventive care recommended by AHA/ASA guidelines for prevention of ICH.

---

### 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association / American stroke association [^1122fzqk]. Stroke (2021). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to antiplatelet therapy, AHA/ASA 2021 guidelines recommend to insufficient evidence regarding the effectiveness of increasing the dose of aspirin or changing to another antiplatelet medication in patients already taking aspirin at the time of non-cardioembolic ischemic stroke or TIA.

---

### Should patients with minor strokes be given thrombolytics? [^113UgRyf]. Stroke and Vascular Neurology (2025). Medium credibility.

Different criteria of minor stroke

A NIHSS ≤ 3 or ≤ 5 were widely used to define a minor stroke, although the consensus is still lacking.

---

### 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association / American stroke association [^1151Hdsx]. Stroke (2021). High credibility.

Regarding medical management for transient ischemic attack, more specifically with respect to antithrombotic therapy, intracranial atherosclerotic disease, AHA/ASA 2021 guidelines recommend to initiate aspirin 325 mg/day over warfarin to reduce the risk of recurrent ischemic stroke and vascular death in patients with a TIA caused by 50–99% stenosis of a major intracranial artery.

---

### 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association / American stroke association [^111EXF5b]. Stroke (2021). High credibility.

Regarding medical management for transient ischemic attack, more specifically with respect to antithrombotic therapy, intracranial atherosclerotic disease, AHA/ASA 2021 guidelines recommend to consider initiating clopidogrel 75 mg/day, in addition to aspirin, for up to 90 days to further reduce the risk of recurrent stroke in patients with a recent (within 30 days) TIA attributable to severe stenosis (70–99%) of a major intracranial artery.

---

### 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association / American stroke association [^115xswAf]. Stroke (2021). High credibility.

Regarding medical management for transient ischemic attack, more specifically with respect to antithrombotic therapy, non-cardioembolic TIA, AHA/ASA 2021 guidelines recommend to initiate antiplatelet therapy over oral anticoagulation to reduce the risk of recurrent ischemic stroke and other cardiovascular events while minimizing the risk of bleeding in patients with a non-cardioembolic TIA.

---

### European Stroke Organisation guidelines on treatment of patients with intracranial atherosclerotic disease [^114fMQLC]. European Stroke Journal (2022). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to antiplatelet therapy, ESO 2022 guidelines recommend to insufficient evidence to recommend an additional infusion of glycoprotein IIb/IIIa inhibitors after initial mechanical thrombectomy in patients with AIS due to an intracranial atherosclerotic disease-related intracranial arterial occlusion.

---

### 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association / American stroke association [^112Z5bZ9]. Stroke (2021). High credibility.

Regarding preventative measures for acute ischemic stroke, more specifically with respect to secondary prevention (antiplatelet therapy), AHA/ASA 2021 guidelines recommend to initiate aspirin 325 mg/day over warfarin to reduce the risk of recurrent ischemic stroke and vascular death in patients with stroke or TIA caused by 50–99% stenosis of a major intracranial artery.

---

### 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^116yMQmA]. Stroke (2018). Medium credibility.

Malignant middle cerebral artery infarction ≤ 60 years — in patients ≤ 60 years of age with unilateral MCA infarctions who deteriorate neurologically within 48 hours despite medical therapy, decompressive craniectomy with dural expansion is reasonable because it reduces mortality by close to 50%, with 55% of the surgical survivors achieving moderate disability (able to walk) or better (mRS score 2 or 3) and 18% achieving independence (mRS score ≤ 2) at 12 months; randomized trials showed an absolute risk reduction in mortality of 50% (95% CI, 34–66) at 12 months.

---

### 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association / American stroke association [^111id932]. Stroke (2021). High credibility.

Regarding medical management for transient ischemic attack, more specifically with respect to antithrombotic therapy, intracranial atherosclerotic disease, AHA/ASA 2021 guidelines recommend to consider initiating cilostazol 200 mg/day, in addition to aspirin or clopidogrel, to reduce the risk of recurrent stroke in patients with a TIA attributable to 50–99% stenosis of a major intracranial artery.

---

### Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^1151QBwL]. Stroke (2019). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to antiplatelet therapy, AHA/ASA 2019 guidelines recommend to insufficient evidence to support increasing the dose of aspirin or switching to an alternative antiplatelet agent for an additional benefit in secondary stroke prevention in patients experiencing a noncardioembolic AIS while taking aspirin.

---

### 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association / American stroke association [^113bmhte]. Stroke (2021). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to antiplatelet therapy, AHA/ASA 2021 guidelines recommend to initiate aspirin 50–325 mg daily, clopidogrel 75 mg, or the combination of aspirin 25 mg and extended-release dipyridamole 200 mg BID for secondary prevention of ischemic stroke in patients with non-cardioembolic ischemic stroke or TIA.

---

### 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association / American stroke association [^1164WDRJ]. Stroke (2021). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to antiplatelet therapy, AHA/ASA 2021 guidelines recommend to consider initiating dual antiplatelet therapy with ticagrelor plus aspirin for 30 days to reduce the risk of 30-day recurrent stroke in patients with the following, recognizing that it also may increase the risk of serious bleeding events, including Intracerebral hemorrhage:

- recent (< 24 hours) minor-to-moderate stroke (NIHSS score ≤ 5)

- high-risk TIA (ABCD² score ≥ 6)

- symptomatic intracranial or extracranial ≥ 30% stenosis of an artery that could account for the event.

---

### 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association / American stroke association [^112kBnsM]. Stroke (2021). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to antiplatelet therapy, AHA/ASA 2021 guidelines recommend to initiate antiplatelet therapy over oral anticoagulation to reduce the risk of recurrent ischemic stroke and other cardiovascular events while minimizing the risk of bleeding in patients with non-cardioembolic ischemic stroke or TIA.

---

### Stroke in 2012: major advances in the treatment of stroke [^115mbS5d]. Nature Reviews: Neurology (2013). Medium credibility.

Several clinical trials and experimental studies that could have a major impact on the treatment of patients with ischaemic stroke were published in 2012. The studies cover all therapeutic options, including stroke prevention, recanalization and thrombolysis, neuroprotection, and promising new therapeutic approaches focused on neurorepair.

---

### Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^111DjRzj]. Stroke (2019). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to anticoagulant therapy, AHA/ASA 2019 guidelines recommend to insufficient evidence to support the use of oral factor Xa inhibitors for the treatment of patients with AIS.

---

### Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^114NjF6Z]. Stroke (2019). High credibility.

Acute ischemic stroke (AIS) antithrombotic treatment — agent selection: For early secondary prevention in patients with noncardioembolic AIS, the selection of an antiplatelet agent should be individualized on the basis of patient risk factor profiles, cost, tolerance, relative known efficacy of the agents, and other clinical characteristics.

---

### 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association / American stroke association [^113T7Tbj]. Stroke (2021). High credibility.

Regarding medical management for transient ischemic attack, more specifically with respect to antithrombotic therapy, non-cardioembolic TIA, AHA/ASA 2021 guidelines recommend to consider initiating dual antiplatelet therapy with ticagrelor plus aspirin for 30 days to reduce the risk of 30-day recurrent stroke in patients with a high-risk TIA (ABCD² score ≥ 6) and symptomatic intracranial or extracranial ≥ 30% stenosis of an artery that could account for the event, recognizing that it also may increase the risk of serious bleeding events, including Intracerebral hemorrhage.

---

### 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association / American stroke association [^117B1Avd]. Stroke (2021). High credibility.

Regarding medical management for transient ischemic attack, more specifically with respect to antithrombotic therapy, intracranial atherosclerotic disease, AHA/ASA 2021 guidelines recommend to consider initiating ticagrelor 90 mg BID, in addition to aspirin, for up to 30 days to further reduce the risk of recurrent stroke in patients with a recent (within 24 hours) high-risk TIA and concomitant ipsilateral > 30% stenosis of a major intracranial artery.

---

### Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^1174rfZW]. Stroke (2019). High credibility.

Hemorrhagic transformation in acute ischemic stroke (AIS) — for patients with AIS and HT, initiation or continuation of antiplatelet or anticoagulation therapy may be considered depending on the clinical scenario and underlying indication.

---

### Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^114W4QKL]. Stroke (2019). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to antiplatelet therapy, AHA/ASA 2019 guidelines recommend to individualize the selection of antiplatelet agents for early secondary prevention in patients with noncardioembolic AIS based on patient risk factor profiles, cost, tolerance, relative known efficacy of the agents, and other clinical characteristics.

---

### 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association / American stroke association [^111Kr9Nb]. Stroke (2021). High credibility.

Regarding specific circumstances for acute ischemic stroke, more specifically with respect to patients with valvular heart disease (antithrombotic therapy), AHA/ASA 2021 guidelines recommend to initiate long-term therapy with aspirin in preference to long-term anticoagulation to reduce the risk of recurrent stroke or TIA in patients with a bioprosthetic aortic or mitral valve, a history of ischemic stroke or TIA before valve replacement, and no other indication for anticoagulation therapy beyond 3–6 months from the valve placement.

---

### 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association / American stroke association [^117KKwGz]. Stroke (2021). High credibility.

Organization, review, and approval — governance states that the writing group included representatives from the American Heart Association/American Stroke Association (AHA/ASA) and the American Academy of Neurology; the document was reviewed by AHA oversight and executive committees and by reviewers from the American Academy of Neurology, the Society of Vascular and Interventional Neurology, and the American Association of Neurological Surgeons and Congress of Neurological Surgeons, as well as by 55 individual content reviewers; it was approved for publication by the governing bodies of the American Stroke Association (ASA) and the American Heart Association (AHA), endorsed by the American Association of Neurological Surgeons and Congress of Neurological Surgeons and by the Society of Vascular and Interventional Neurology, and the American Academy of Neurology affirmed the value of the guideline.

---

### European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke [^1133MTDE]. European Stroke Journal (2023). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to intravenous tenecteplase, ESO 2023 guidelines recommend to do not administer tenecteplase 0.25 mg/kg in patients with AIS on awakening from sleep or AIS of unknown onset selected with no brain imaging other than plain CT, unless within the context of a clinical trial.

---

### El enfoque de orientación cognitiva al desempeño ocupacional diario en discapacidades con origen en la infancia [^1136V2gA]. Developmental Medicine and Child Neurology (2025). Medium credibility.

Recomendación 5. Mecanismos subyacentes del cambio

Faltan estudios que identifiquen los ingredientes activos y los mecanismos de cambio, incluidos los resultados relacionados con la transferencia, tal como se definió anteriormente. Para comprender el mecanismo de acción del enfoque CO‐OP, es necesario identificar los procesos activos y/o componentes del tratamiento y probar cómo conducen a resultados positivos. Comprender por qué funciona CO‐OP, a través de qué procesos y cómo ocurre el cambio en diferentes poblaciones, permitiría entender los mecanismos de cambio terapéutico.

Comprender si existen mediadores y moderadores específicos de la eficacia ayudará a desentrañar los mecanismos subyacentes de acción. La evidencia en neurociencias, como la comprensión de las vías de la actividad motora y cómo actúa CO‐OP en términos de vías neuronales e interacciones, podría ser útil para refinar la intervención y proporcionar tratamientos personalizados. Comprender el impacto de CO‐OP en el neurodesarrollo y en las vías cognitivas‐motoras, especialmente en niños con discapacidades complejas, podría perfeccionar el enfoque y orientar hacia tratamientos más personalizados.

---

### Thrombolysis for ischaemic stroke despite direct oral anticoagulation [^113HXx9A]. Stroke and Vascular Neurology (2024). Medium credibility.

Intravenous thrombolysis is not recommended in anticoagulated patients receiving direct oral anticoagulants (DOACs) and a recent intake within the last 48hours in US and European guidelines. However, three observational studies now suggest safety of thrombolysis in patients with recent intake of DOACs, and thus support previous experimental data. In this perspective, the current evidence and practical consequences are discussed.

---

### Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^115SuTXE]. Stroke (2019). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to anticoagulant therapy, AHA/ASA 2019 guidelines recommend to insufficient evidence to recommend short-term anticoagulation in patients with non-occlusive, extracranial intraluminal thrombus in the setting of AIS.

---

### Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke [^111wb8pa]. Nature Reviews: Neurology (2012). Medium credibility.

Antiplatelet therapy is more effective than anticoagulation for the prevention of noncardioembolic ischaemic stroke. The choice of antiplatelet regimen, however, remains contentious. Recent controversies regarding aspirin resistance and the optimal dosing of aspirin, as well as recognition of the variable bioactivation of clopidogrel, have added further confusion to the debate. The American Heart Association (AHA) and American Stroke Association (ASA) recently released their third joint guideline in the past 5 years on secondary stroke prevention. The European Stroke Organisation has published three guidelines on this issue since 2000. These frequent updates have been necessary because of rapidly accumulating data from clinical trials. Careful consideration of the sometimes confusing trial results reveals that the 2011 AHA-ASA guidelines are correct in no longer specifying a 'preferred' antiplatelet regimen from among the choices recently studied. This recommendation does not, however, mean that all antiplatelet regimens should be considered equal. This Review discusses the various antiplatelet regimens, and the trials that led to the rapid evolution of the guidelines for secondary prevention of ischaemic stroke.

---

### Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^114neEki]. Stroke (2019). High credibility.

Neuroprotective agents in AIS are addressed as follows: At present, pharmacological or nonpharmacological treatments with putative neuroprotective actions are not recommended.

---

### Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^116T9EPZ]. Stroke (2019). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to anticoagulant therapy, AHA/ASA 2019 guidelines recommend to insufficient evidence to support the use of argatroban, dabigatran, or other thrombin inhibitors for the treatment of patients with AIS.

---

### Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^1146S1LU]. Stroke (2019). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to antiplatelet therapy, AHA/ASA 2019 guidelines recommend to insufficient evidence to support the use of IV tirofiban or eptifibatide for the treatment of AIS.
Do not use IV abciximab for the treatment of AIS.

---

### 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association / American stroke association [^1176Eung]. Stroke (2021). High credibility.

Regarding specific circumstances for transient ischemic attack, more specifically with respect to patients with valvular heart disease (antithrombotic therapy), AHA/ASA 2021 guidelines recommend to initiate long-term therapy with aspirin in preference to long-term anticoagulation to reduce the risk of recurrent TIAs in patients with a bioprosthetic aortic or mitral valve, a history of TIA before valve replacement, and no other indication for anticoagulation therapy beyond 3–6 months from the valve placement.

---

### 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association / American stroke association [^113UDm6p]. Stroke (2021). High credibility.

Regarding specific circumstances for acute ischemic stroke, more specifically with respect to patients with valvular heart disease (antithrombotic therapy), AHA/ASA 2021 guidelines recommend to consider initiating anticoagulation with higher-intensity warfarin to achieve an INR of 3.0 (range 2.5–3.5) or adding aspirin 75–100 mg/day to reduce the risk of thromboembolic events in patients with a mechanical aortic valve and a history of ischemic stroke or TIA.

---

### Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^116ZQapF]. Stroke (2019). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to antiplatelet therapy, AHA/ASA 2019 guidelines recommend to do not use aspirin as a substitute for acute stroke treatment in patients otherwise eligible for IV alteplase or mechanical thrombectomy.

---

### Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [^115k2tkY]. Chest (2012). Medium credibility.

Guideline grading — strength and quality of evidence: We generated treatment recommendations (Grade 1) and suggestions (Grade 2) based on high (A), moderate (B), and low (C) quality evidence.

---

### Clinical policy: critical issues in the evaluation of adult patients with suspected transient ischemic attack in the emergency department [^111uWPM1]. Annals of Emergency Medicine (2016). Medium credibility.

AHA/ASA admission guidance and early risk timeframe — ED patients with suspected TIA: "A subset of ED patients with TIA are at increased risk for strokes in the days and weeks after the index ED presentation". The page notes, "The 2009 AHA/ASA TIA guidelines recommend hospital admission for (1) individuals with ABCD2 score greater than or equal to 3, (2) those with ABCD2 score 0 to 2 if 'uncertain that diagnostic workup can be completed within 2 days as an outpatient', or (3) when 'other evidence indicates the patient's event was caused by focal ischemia'. It also specifies increased short-term risk "(ie, 2 to 7 days) for stroke".

---

### Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^114LtvgY]. Stroke (2019). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to management of dyslipidemia, AHA/ASA 2019 guidelines recommend to consider adding a PCSK9 inhibitor after a clinician-patient discussion about the net benefit, safety, and cost in patients with clinical ASCVD judged to be very high risk and on maximally tolerated LDL-C-lowering therapy with LDL-C ≥ 70 mg/dL (≥ 1.8 mmol/L) or non-HDL-C ≥ 100 mg/dL (≥ 2.6 mmol/L).

---

### European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke [^112pF2QV]. European Stroke Journal (2023). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to intravenous tenecteplase, ESO 2023 guidelines recommend to consider administering tenecteplase 0.25 mg/kg as an alternative to alteplase 0.9 mg/kg in patients with AIS of < 4.5 hours duration eligible for IV thrombolysis.
Consider preferring tenecteplase 0.25 mg/kg over alteplase 0.9 mg/kg in these patients in light of safety and efficacy data and because tenecteplase can be administered with a single bolus rather than a 1-hour infusion.
Do not use tenecteplase at a dose of 0.40 mg/kg.

---

### Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^1141CBNo]. Stroke (2019). High credibility.

Regarding therapeutic procedures for acute ischemic stroke, more specifically with respect to technical considerations for thrombectomy, AHA/ASA 2019 guidelines recommend to insufficient evidence to recommend IV glycoprotein IIb/IIIa inhibitors administration during endovascular stroke treatment.

---

### Clinical policy: use of thrombolytics for the management of acute ischemic stroke in the emergency department [^116McpZY]. Annals of Emergency Medicine (2024). High credibility.

Observational evidence — Catalonia registry analysis (Abilleira et al.) comparing EVT alone with intravenous thrombolysis plus EVT (IVT + EVT) reported that after adjustment for baseline differences there were no differences between groups in 90-day mortality, symptomatic bleeding at 24 to 36 hours, or mRS 0 to 2.

---

### Clinical policy: use of thrombolytics for the management of acute ischemic stroke in the emergency department [^1167hAhr]. Annals of Emergency Medicine (2024). High credibility.

Acute ischemic stroke endovascular treatment (EVT) with or without prior intravenous thrombolysis (IVT) in a regional registry retrospective cohort from Catalonia, Spain reported N = 1,166 with 599 receiving EVT only and 567 IVT followed by EVT; the odds ratios were OR for modified Rankin Scale (mRS) 0 to 2 at 90 d 0.97 (95% CI 0.74 to 1.27), OR for death 1.07 (95% CI 0.74 to 1.54), and OR for symptomatic bleeding 0.56 (95% CI 0.25 to 1.27).

---

### Effect of intra-arterial alteplase vs placebo following successful thrombectomy on functional outcomes in patients with large vessel occlusion acute ischemic stroke: the CHOICE randomized clinical trial [^1144n562]. JAMA (2022). Excellent credibility.

The study CHOICE (alteplase) was published by Arturo Renú and colleagues in 2022 in the journal JAMA. This study is related to the following diseases: Acute ischemic stroke. In the CHOICE (alteplase) study, the trial question was: what is the effect of intra-arterial alteplase in patients with large vessel occlusion AIS? In the CHOICE (alteplase) study, the study design was: multi-center, double blinded, RCT. In the CHOICE (alteplase) study, the population was: 113 patients (52 female, 61 male). The inclusion criteria were patients with large vessel occlusion AIS and successful reperfusion following thrombectomy. The key exclusion criteria were contraindication to the use of intravenous alteplase; NIHSS score on admission > 25; complete clinical recovery in the angiography suite during the procedure. In the CHOICE (alteplase) study, the interventions were: n = 61 alteplase (intra-arterial infusion of a dose of 0.225 mg/kg over 15–30 minutes) n = 52 placebo (intra-arterial infusion of a matching placebo over 15 minutes). In the CHOICE (alteplase) study, the primary outcome was: significant increase in patients with mRS score of < 2 at 90 days (59% vs. 40.4%; AD 18.4%, 95% CI 0.3 to 36.4). In the CHOICE (alteplase) study, the secondary outcomes were: no significant difference in patients with improved angiographic eTICI score (8.5% vs. 7.7%; AD 0.6%, 95% CI -9.5 to 10.7) No significant difference in patients with infarct expansion (63.9% vs. 74.5%; ARD -8.9, 95% CI -25.6 to 7.9) No significant difference in patients with ischemic worsening (1.6% vs. 5.8%; ARD -4.9, 95% CI -18 to 8.3). In the CHOICE (alteplase) study, the safety outcomes were: no significant differences in symptomatic ICH, death at day 90. In the CHOICE (alteplase) study, the conclusion was: in patients with large vessel occlusion AIS and successful reperfusion following thrombectomy, alteplase was superior to placebo with respect to patients with mRS score of < 2 at 90 days.

---

### 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association / American stroke association [^113rEzDk]. Stroke (2021). High credibility.

Regarding preventative measures for acute ischemic stroke, more specifically with respect to secondary prevention (antiplatelet therapy), AHA/ASA 2021 guidelines recommend to consider initiating ticagrelor 90 mg BID, in addition to aspirin, for up to 30 days to further reduce the risk of recurrent stroke in patients with recent (within 24 hours) minor stroke or high-risk TIA and concomitant ipsilateral > 30% stenosis of a major intracranial artery.

---

### Thrombus migration in ischemic stroke due to large vessel occlusion: a question of time [^1168V9Ai]. Journal of Neurointerventional Surgery (2023). Medium credibility.

Objective

This study aimed to assess prevalence and associated factors of TM as well as its impact on technical and functional outcome after EVT.

---

### 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^115V4CJj]. Stroke (2018). Medium credibility.

AHA/ASA acute ischemic stroke — post–intravenous (IV) alteplase antithrombotic therapy: The risk of antithrombotic therapy within the first 24 hours after treatment with IV alteplase (with or without endovascular therapy) is stated as uncertain, and use might be considered only when concomitant conditions make such treatment beneficial or withholding it poses substantial risk.

---

### Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^114AwBmu]. Stroke (2019). High credibility.

Acute ischemic stroke — evidence, consent, and dose variant notes that the safety and efficacy of this treatment when administered within the first 3 hours after stroke onset are solidly supported by combined data from multiple RCTs and confirmed by extensive community experience in many countries, that when a patient cannot provide consent and a legally authorized representative is not immediately available it is justified to proceed with IV alteplase in an otherwise eligible adult patient with a disabling AIS, and that a lower dose of IV alteplase (0.6 mg/kg) was not shown to be noninferior to standard-dose IV alteplase for the reduction of death and disability at 90 days.

---

### 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association / American stroke association [^1178QSdg]. Stroke (2021). High credibility.

Regarding specific circumstances for acute ischemic stroke, more specifically with respect to patients with valvular heart disease (antithrombotic therapy), AHA/ASA 2021 guidelines recommend to initiate aspirin 75–100 mg/day in addition to warfarin with an INR target of 3.0 (range 2.5–3.5) to reduce the risk of thrombosis and recurrent stroke or TIA in patients with a mechanical mitral valve and a history of ischemic stroke or TIA before valve replacement.

---

### Stroke thrombectomy in patients with COVID-19: initial experience in 13 cases [^116Hwhfa]. AJNR: American Journal of Neuroradiology (2020). Medium credibility.

We performed a retrospective review in both comprehensive stroke units of a region affected early by the coronavirus disease 2019 (COVID-19) pandemic, between March 1 and April 26, 2020, including patients with COVID-19 who underwent mechanical thrombectomy for ischemic stroke. We identified 13 cases, representing 38.2% of 34 thrombectomies performed during this period. We observed increased mortality and a high incidence of thrombotic complications during hospitalization. Given the high rate of infected patients, systematic use of full personal protection measures seems justified.

---

### Clinical policy: use of intravenous tissue plasminogen activator for the management of acute ischemic stroke in the emergency department [^112xJjY5]. Annals of Emergency Medicine (2015). Medium credibility.

Acute ischemic stroke — Clark et al randomized double-blind trial of IV tPA 0.9 mg/kg in a 3- to 5-h window (N = 613) assessed National Institutes of Health Stroke Scale (NIHSS) ≤ 1 at 90 days, symptomatic intracranial hemorrhage (SICH), and 90-day mortality; excellent outcome was 32% with placebo versus 34% with tPA (P = 0.65), SICH was 1.1% with placebo versus 7.0% with tPA (P < .001), and 90-day mortality was 6.9% with placebo versus 11% with tPA (P = 0.09). The multicenter trial "did not show benefit of tPA in the 3- to 5-h time window", and the mean time to treatment was 4 h 28 min.

---

### 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^115npvgM]. Stroke (2018). Medium credibility.

Sonothrombolysis — adjuvant to IV thrombolysis: The use of sonothrombolysis as adjuvant therapy with IV thrombolysis is not recommended.

---

### Therapeutic anticoagulation can be safely accomplished in selected patients with traumatic intracranial hemorrhage [^114vc7Pz]. World Journal of Emergency Surgery (2012). Low credibility.

Herein, we developed a study with the following objectives: (1) to evaluate the likelihood of extension of intracranial bleeding after the introduction of therapeutic anticoagulation; and (2) to evaluate the time course associated with introduction of therapeutic anticoagulation after the initial injury.

---

### Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^112ybapJ]. Stroke (2019). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to intravenous alteplase (concomitant thrombectomy), AHA/ASA 2019 guidelines recommend to administer IV alteplase in patients eligible for IV alteplase even if mechanical thrombectomy is being considered.

---

### Thrombolysis and mechanical thrombectomy for arterial disease [^115UebUF]. The Surgical Clinics of North America (2004). Low credibility.

Thrombolytic therapy has been around for close to 30 years now, but its exact role in the treatment of acute and chronic arterial occlusive disease continues to be debated. Studies have produced varying and contradictory results. We are still not sure if thrombolysis has any true advantages over surgical thromboembolectomy, or which lytic agent is the best. Nonetheless, the technique still plays an important role in the treatment of arterial occlusions.

---

### Clinical policy: use of intravenous tissue plasminogen activator for the management of acute ischemic stroke in the emergency department [^112JyvWP]. Annals of Emergency Medicine (2015). Medium credibility.

Hacke et al — randomized, double-blind trial of intravenous tissue plasminogen activator (tPA) 0.9 mg/kg (N = 800) using modified Rankin Scale (mRS) ≤ 1 at 90 days found mRS ≤ 1 in 40.3% of the treatment group vs 36.6% with placebo (P = 0.28), symptomatic intracranial hemorrhage 8.8% with tPA vs 3.4% with placebo, and mortality 10.6% (both groups); the multicenter trial did not show benefit, including among patients treated from 0–3 h with low numbers (158/800), and overall mortality was lower in ECASS II (10.6%) compared with NINDS (17% in the tPA group), while good outcomes in the ECASS II placebo group (36.6%) were close to the tPA outcomes in NINDS (39%).

---

### Antithrombotic therapy in arterial thrombosis and thromboembolism in COVID-19: an American College of Chest Physicians expert panel report [^114vuKD5]. Chest (2023). High credibility.

COVID-19 — hospitalized patients with an acute stroke or transient ischemic attack (TIA) of no established etiology: we suggest treatment with antiplatelet therapy as per current recommendations for non-COVID-19 patients.

---

### 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^116C3U7o]. Stroke (2018). Medium credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to intravenous alteplase, bleeding risk, AHA/ASA 2018 guidelines recommend to insufficient evidence regarding the safety and efficacy of IV alteplase in patients with a clinical history of potential bleeding diathesis or coagulopathy. Consider administering IV alteplase on a case-by-case basis.

---

### Alteplase (Activase) [^112cwcM9]. FDA (2025). Medium credibility.

Labeled indications for Alteplase (also known as Activase, Cathflo Activase) include:

- Treatment of acute ischemic stroke in adults
- Treatment of myocardial infarction in adults
- Treatment of pulmonary embolism in adults

Off-label indications for Alteplase (also known as Activase, Cathflo Activase) include:

- Treatment of cardiac arrest in adults with pulmonary embolism

---

### 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^113j5LuN]. Stroke (2018). Medium credibility.

Tenecteplase — dose and conditional role: Tenecteplase administered as a 0.4‑mg/kg single IV bolus has not been proven to be superior or noninferior to alteplase but might be considered as an alternative to alteplase in patients with minor neurological impairment and no major intracranial occlusion, and tenecteplase is given as a single IV bolus as opposed to the 1‑hour infusion of alteplase.

---

### Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^117JbgHX]. Stroke (2019). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to intravenous tenecteplase, AHA/ASA 2019 guidelines recommend to consider administering tenecteplase (single IV bolus of 0.4-mg/kg) as an alternative to alteplase in patients with minor neurological impairment and no major intracranial occlusion.

---

### Intravenous thrombolysis for acute ischemic stroke [^111uGGTW]. Journal of Vascular and Interventional Radiology (2004). Low credibility.

Intravenous recombinant tissue-type plasminogen activator (rtPA, alteplase) is the only drug approved for the treatment of acute ischemic stroke. It should be administered within 3 hours of stroke. There is additional evidence, however, that administration at later times, by means of other methods, is effective. Herein, is a broad review of the knowledge gained and insights created from studies in which thrombolytic treatment was used in patients with stroke.

---

### Antiplatelet agents for the treatment and prevention of coronary atherothrombosis [^113jZEx4]. Journal of the American College of Cardiology (2017). Low credibility.

Antiplatelet drugs provide first-line antithrombotic therapy for the management of acute ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their recurrence. Their role in the primary prevention of atherothrombosis remains controversial because of the uncertain balance of the potential benefits and risks when combined with other preventive strategies. The aim of this consensus document is to review the evidence for the efficacy and safety of antiplatelet drugs, and to provide practicing cardiologists with an updated instrument to guide their choice of the most appropriate antiplatelet strategy for the individual patient presenting with different clinical manifestations of coronary atherothrombosis, in light of comorbidities and/or interventional procedures.

---

### Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [^115ALPf9]. Chest (2012). Medium credibility.

Acute ischemic stroke — intravenous recombinant tissue plasminogen activator (r-tPA) timing: In patients with acute ischemic stroke in whom treatment can be initiated within 3 h of symptom onset, we recommend IV recombinant tissue plasminogen activator (r-tPA) over no IV r-tPA (Grade 1A); in those in whom treatment can be initiated within 4.5 h but not within 3 h of symptom onset, we suggest IV r-tPA over no IV r-tPA (Grade 2C); and if treatment cannot be initiated within 4.5 h of symptom onset, we recommend against IV r-tPA (Grade 1B).

---

### Tenecteplase versus alteplase for acute ischaemic stroke: a meta-analysis of phase III randomised trials [^117KVwv1]. Stroke and Vascular Neurology (2024). Medium credibility.

Conclusions

Our study elucidated that TNK was non-inferior to alteplase when treating AIS patients within 4.5 hours of onset and resulted in excellent functional outcomes at 90 days. Its safety profiles were also compatible to alteplase. Like alteplase, TNK can be used to treat all AIS patients presented within 4.5 hours. Therefore, the current meta-analysis strongly recommends TNK as an alternative to alteplase.

---

### European Stroke Organisation (ESO) guidelines for prophylaxis for venous thromboembolism in immobile patients with acute ischaemic stroke [^115Wesn8]. European Stroke Journal (2016). Medium credibility.

Regarding inpatient care for acute ischemic stroke, more specifically with respect to thromboprophylaxis, anticoagulation, ESO 2016 guidelines recommend to consider administering prophylactic anticoagulation with UFH (5,000 U BID or TID) or LMWH or heparinoids in immobile patients with AIS if the benefits of reducing the risk of VTE is high enough to offset the increased risks of intracranial and extracranial bleeding associated with their use.

---

### Tenecteplase (Tnkase) [^115yBrps]. FDA (2025). Medium credibility.

Labeled indications for Tenecteplase (also known as TNKase, TNKase) include:

- Treatment of ST-elevation myocardial infarction in adults
- Treatment of acute ischemic stroke in adults

Off-label indications for Tenecteplase (also known as TNKase, TNKase) include:

- Treatment of pulmonary embolism in adults
- Treatment of cardiac arrest in adults with pulmonary embolism

---

### Clinical policy: use of thrombolytics for the management of acute ischemic stroke in the emergency department [^114K6U2d]. Annals of Emergency Medicine (2024). High credibility.

Observational and retrospective evidence — adult acute ischemic stroke (AIS) patients within 6 h of onset with imaging-confirmed anterior circulation occlusion in a retrospective registry cohort from 3 stroke centers in France were evaluated for mRS of 0 to 2 at 90 d and sICH; among N = 1,507, 65% received intravenous thrombolytics and 407 were propensity score matched with multiple imputation; in propensity-matched results, mRS of 0 to 2 was 49% in the thrombolytics plus thrombectomy group versus 45% in the thrombectomy only group (OR 1.21 [95% CI 0.90 to 1.63], P = 0.21), and sICH was 9% for the thrombolytic plus thrombectomy versus 7% for the thrombectomy only group (OR 1.21 [95% CI 0.70 to 2.09, P = 0.5]); limitations included propensity score methods with residual confounding and no apparent blinding for outcome assessment.

---

### European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke [^111iPm2Z]. European Stroke Journal (2023). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to intravenous tenecteplase, ESO 2023 guidelines recommend to administer tenecteplase 0.25 mg/kg over alteplase 0.9 mg/kg in patients with large vessel occlusion AIS of < 4.5 hours duration eligible for IV thrombolysis while not should delaying mechanical thrombectomy.
Consider administering tenecteplase 0.25 mg/kg or 0.40 mg/kg over skipping IV thrombolysis in these patients directly admitted to a thrombectomy-capable center. Consider administering tenecteplase 0.25 mg/kg followed by rapid transfer to a thrombectomy-capable center in patients admitted to a center without mechanical thrombectomy capability.

---

### Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^114xaX5V]. Stroke (2019). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to intravenous alteplase, bleeding risk, AHA/ASA 2019 guidelines recommend to do not administer abciximab concurrently with IV alteplase.

---

### Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4. 5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial [^115Ghmzj]. The Lancet: Neurology (2024). High credibility.

The study TASTE was published by Mark W Parsons and colleagues in 2024 in the journal Lancet Neurol. This study is related to the following diseases: Acute ischemic stroke. In the TASTE study, the trial question was: is tenecteplase noninferior to alteplase in patients with AIS within 4.5 hours of onset? In the TASTE study, the study design was: multi-center, open label, RCT. In the TASTE study, the population was: 680 patients (260 female, 420 male). The inclusion criteria were adult patients with AIS within 4.5 hours of onset or last known well who were selected by perfusion imaging. The key exclusion criteria were ICH; pre-stroke mRS score ≥ 2; previous stroke within last 3 months; clinically significant hypoglycemia; uncontrolled hypertension; known hypersensitivity to alteplase/tenecteplase. In the TASTE study, the interventions were: n = 339 tenecteplase (at a dose of 0.25 mg/kg) n = 341 alteplase (at a dose of 0.90 mg/kg). In the TASTE study, the primary outcome was: difference not exceeding non-inferiority margin in mRS score of 0–1 at 3 months, per-protocol analysis (59% vs. 56%; SRD 0.05, 95% CI -0.02 to 0.12). In the TASTE study, the secondary outcomes were: significant decrease in mRS score of 0–1 at 3 months, intention-to-treat analysis (57% vs. 55%; SRD 0.03, 95% CI -0.03 to 0.1) Significant decrease in symptomatic ICH (3% vs. 2%; RD 0.01, 95% CI -0.01 to 0.03) Significant decrease in death at day 90 (7% vs. 4%; SRD 0.02, 95% CI -0.02 to 0.05). In the TASTE study, the conclusion was: in adult patients with AIS within 4.5 hours of onset or last known well who were selected by perfusion imaging, tenecteplase was noninferior to alteplase with respect to mRS score of 0–1 at 3 months, per-protocol analysis.

---

### 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^1116gXBM]. Stroke (2018). Medium credibility.

Regarding specific circumstances for acute ischemic stroke, more specifically with respect to patients with intracranial neoplasms, AHA/ASA 2018 guidelines recommend to consider administering IV alteplase in patients with AIS harboring an extra-axial intracranial neoplasm.

---

### Clinical policy: use of thrombolytics for the management of acute ischemic stroke in the emergency department [^111v13iY]. Annals of Emergency Medicine (2024). High credibility.

SWIFT DIRECT — anterior circulation stroke randomized comparison: In 408 patients across 48 EVT-capable centers, the primary outcome was mRS 0 to 2 at 90 days; per-protocol neurologic outcomes occurred in 57% with EVT alone versus 64% with IVT + EVT, the absolute risk difference was −4.6% (95% CI −14.8 to 5.8%) with a 1-sided 95% CI lower limit of −13.2%, the lower limit exceeded the prespecified 12% and noninferiority of EVT alone could not be concluded, and there was no statistical difference in sICH or mortality by 90 days between groups.

---

### Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^113s2zGD]. Stroke (2019). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to intravenous alteplase (post-administration care), AHA/ASA 2019 guidelines recommend to insufficient evidence regarding the risk of antithrombotic therapy (other than IV aspirin) within the first 24 hours after treatment with IV alteplase (with or without mechanical thrombectomy). Consider initiating antithrombotic therapy in the presence of concomitant conditions for which such treatment given in the absence of IV alteplase is known to provide a substantial benefit or withholding such treatment is known to cause substantial risk.

---

### European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke [^112XXFrs]. European Stroke Journal (2023). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to intravenous tenecteplase, ESO 2023 guidelines recommend to consider administering tenecteplase 0.25 mg/kg over alteplase 0.90 mg/kg to increase the rate of early reperfusion and to shorten the time from imaging to treatment initiation in patients with AIS of < 4.5 hours duration eligible for IV thrombolysis receiving prehospital management in a mobile stroke unit.

---

### Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^114KZSf3]. Stroke (2019). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to intravenous alteplase (pre-administration evaluation), AHA/ASA 2019 guidelines recommend to obtain baseline ECG
and troponin assessment not delaying initiation of IV alteplase in patients presenting with AIS.

---

### Clinical performance measures for neurocritical care: a statement for healthcare professionals from the Neurocritical Care Society [^114qye9c]. Neurocritical Care (2020). High credibility.

2014 Spanish Neurological Society guideline — intravenous thrombolysis window and dose: Thrombolytic treatment with IV rtPA dosed at 0.9 mg/kg is recommended for acute cerebral infarct up to 4.5 hours after stroke onset, performed as early as possible with strict adherence to selection criteria (Level of evidence 1a; grade A recommendation).

---

### 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association / American stroke association [^116NLw2o]. Stroke (2021). High credibility.

Regarding specific circumstances for acute ischemic stroke, more specifically with respect to patients with valvular heart disease (antithrombotic therapy), AHA/ASA 2021 guidelines recommend to initiate antiplatelet therapy to reduce the risk of recurrent stroke or TIA in patients with ischemic stroke or TIA and native aortic or nonrheumatic mitral valve disease (such as mitral annular calcification or mitral valve prolapse) not having AF or another indication for anticoagulation.

---

### Clinical policy: use of intravenous tPA for the management of acute ischemic stroke in the emergency department [^112Cgmhb]. Annals of Emergency Medicine (2013). Medium credibility.

ECASS II — intravenous (IV) tPA (tissue plasminogen activator) 0.9 mg/kg versus placebo in acute ischemic stroke of less than 6 hours used a modified Rankin Scale (mRS) 0 or 1 primary endpoint and found no overall difference (40% versus 37%; p = 0.28) or among those treated within 3 hours (42% versus 38%; p = 0.63); parenchymal hemorrhage occurred in 12% of tPA and 3% of placebo (P < .001), and the 90‑day mortality rate was equal at 11% for both groups (P = 0.99).

---

### Thrombolytic therapy with alteplase for ischaemic stroke [^116JqvJL]. Drug and Therapeutics Bulletin (2009). Low credibility.

Stroke is very common, with, for example, around 110,000 people each year in England alone experiencing a first or recurrent episode. Consequences of stroke can include disability and early death, and the condition costs the UK economy around 7 billion pounds annually. Around 70–80% of first strokes are ischaemic (i.e. due to the thromboembolic or thrombotic occlusion of an intracranial artery), and so some patients with stroke may be suitable for thrombolytic therapy. Here we review the evidence for such therapy in acute ischaemic stroke.

---

### Clinical policy: use of intravenous tissue plasminogen activator for the management of acute ischemic stroke in the emergency department [^113GKouw]. Annals of Emergency Medicine (2015). Medium credibility.

Acute ischemic stroke — Albers et al randomized, double-blind, placebo-controlled trial of IV tPA 0.9 mg/kg evaluated NIHSS ≤ 1 at 90 days, SICH, and 90-day mortality; NIHSS ≤ 1 occurred in 14/23 with tPA versus 10/38 with placebo (P = 0.01), SICH was 3/23 versus 0/38 (P = 0.05), and mortality was 4/23 versus 2/38 (P = 0.12). This was a post hoc analysis of ATLANTIS B patients treated within 3 h of symptom onset.

---

### Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^116esGF8]. Stroke (2019). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to intravenous tenecteplase, AHA/ASA 2019 guidelines recommend to do not use IV defibrinogenating agents or IV fibrinolytic agents other than alteplase and tenecteplase.

---

### Clinical policy: use of intravenous tissue plasminogen activator for the management of acute ischemic stroke in the emergency department [^112pc5JH]. Annals of Emergency Medicine (2015). Medium credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to intravenous alteplase, timing, ACEP 2015 guidelines recommend to administer IV alteplase with a goal to improve functional outcomes in selected patients with AIS within 3 hours after symptom onset at institutions where systems are in place to safely administer the medication. Take the increased risk of symptomatic intracerebral hemorrhage into consideration when deciding whether to administer IV alteplase in patients with AIS.

---

### Clinical policy: use of intravenous tPA for the management of acute ischemic stroke in the emergency department [^115PDWR3]. Annals of Emergency Medicine (2013). Medium credibility.

ATLANTIS — IV tPA (tissue plasminogen activator) 0.9 mg/kg versus placebo initially enrolled patients with stroke symptoms of fewer than 6 hours and was stopped after 142 patients because of increased symptomatic intracerebral hemorrhage in those 5 to 6 hours; ATLANTIS Part B enrolled 0 to 5 hours, randomized 613 patients 1:1 (later changing to 3 to 5 hours). The primary outcome was National Institutes of Health Stroke Scale (NIHSS) 0 or 1 at 90 days, with no overall difference (34% versus 32%; p = 0.65), higher symptomatic intracerebral hemorrhage with tPA (7% versus 1%; P < .001), and a trend toward higher mortality (11% versus 9.6%; p = 0.09); mean time to treatment was 4 hours 28 minutes. Among 61 patients randomized within 3 hours (23 tPA vs 38 placebo), more tPA patients achieved the primary outcome (61% versus 26%; p = 0.01) and had symptomatic intracerebral hemorrhage (13% versus 0%; p = 0.05).

---

### Perioperative care of patients at high risk for stroke during or after non-cardiac, non-neurological surgery: 2020 guidelines from the society for neuroscience in anesthesiology and critical care [^116GX1Ew]. Journal of Neurosurgical Anesthesiology (2020). High credibility.

Respiratory physiology and cerebrovascular reserve — perioperative carbon dioxide tensions may influence cerebrovascular reserve. There are limited data on the interaction between intraoperative PaCO₂ or EtCO₂ and cerebrovascular reserve. Hypocapnia increases cerebrovascular resistance, and maximal resistance may be achieved with PaCO₂ levels that approach 30 mm Hg. Hypercapnia may also impair cerebral blood flow in high-risk brain regions via the steal phenomenon, and the combination of reduced cerebrovascular inflow (eg, hypotension) and impaired vasodilatory reserve (mediated by hypocapnia or hypercapnia) may create conditions for hypoxic-ischemic injury. For patients with preexisting cerebrovascular disease, PaCO₂ may be relevant for cerebrovascular perfusion, with derangements in PaCO₂ reducing cerebrovascular reserve, particular in the setting of hypotension and/or stenotic-occlusive disease.

---

### Vertebrobasilar recanalization after 12 h of onset using balloon expandable stent and thrombolysis [^113S5uoi]. Emergency Radiology (2008). Low credibility.

Basilar artery (BA) thrombosis is a severe condition that has a high percentage of mortality if no treatment is performed. Recanalization is the most successful way of reducing mortality and improving outcome in patients with BA thrombosis. We present a case of a patient that presented to our hospital 12 h after onset of symptoms in which a combination of techniques were used to perform a vertebrobasilar recanalization.

---

### 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^112WgHbj]. Stroke (2018). Medium credibility.

Other IV thrombolytics — non‑alteplase/tenecteplase agents: The benefit of intravenous (IV) defibrinogenating agents and IV fibrinolytic agents other than alteplase and tenecteplase is unproven; therefore, their administration is not recommended outside a clinical trial.

---

### Clinical policy: use of intravenous tissue plasminogen activator for the management of acute ischemic stroke in the emergency department [^115sCoCX]. Annals of Emergency Medicine (2015). Medium credibility.

ECASS II trial — intravenous tissue plasminogen activator (tPA) 0.9 mg/kg versus placebo in acute ischemic stroke of less than 6 hours' duration used a primary endpoint of a modified Rankin Scale score of 0 or 1, with no difference overall (40% versus 37%; p = 0.28) or within 3 hours (42% versus 38%; p = 0.63); parenchymal hemorrhage on posttreatment computed tomography occurred in 12% of tPA and 3% of placebo patients (P < .001), and 90-day mortality was equal at 11% for both groups (P = 0.99).

---

### Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American stroke association [^116q8R2h]. Stroke (2019). High credibility.

Regarding medical management for acute ischemic stroke, more specifically with respect to intravenous alteplase, bleeding risk, AHA/ASA 2019 guidelines recommend to consider administering IV alteplase in otherwise eligible patients previously having a small number (1–10) of cerebral microbleeds on MRI.

---

### Effect of a quality improvement intervention on adherence to therapies for patients with acute ischemic stroke and transient ischemic attack: a cluster randomized clinical trial [^114DvPBX]. JAMA Neurology (2019). High credibility.

Importance

Translating evidence into clinical practice in the management of acute ischemic stroke (AIS) and transient ischemic attack (TIA) is challenging, especially in low- and middle-income countries.

Objective

To assess the effect of a multifaceted quality improvement intervention on adherence to evidence-based therapies for care of patients with AIS and TIA.

Design, Setting and Participants

This 2-arm cluster-randomized clinical trial assessed 45 hospitals and 2336 patients with AIS and TIA for eligibility before randomization. Eligible hospitals were able to provide care for patients with AIS and TIA in Brazil, Argentina, and Peru. Recruitment started September 12, 2016, and ended February 26, 2018; follow-up ended June 29, 2018. Data were analyzed using the intention-to-treat principle.

Interventions

The multifaceted quality improvement intervention included case management, reminders, a roadmap and checklist for the therapeutic plan, educational materials, and periodic audit and feedback reports to each intervention cluster.

Main Outcomes and Measures

The primary outcome was a composite adherence score for AIS and TIA performance measures. Secondary outcomes included an all-or-none composite end point of performance measures, the individual process measure components of the composite end points, and clinical outcomes at 90 days after admission (stroke recurrence, death, and disability measured by the modified Rankin scale).

Results

A total of 36 hospitals and 1624 patients underwent randomization. Nineteen hospitals were randomized to the quality improvement intervention and 17 to routine care. The overall mean (SD) age of patients enrolled in the study was 69.4 (13.5) years, and 913 (56.2%) were men. Overall mean (SD) composite adherence score for the 10 performance measures in the intervention group hospitals compared with control group hospitals was 85.3% (20.1%) vs 77.8% (18.4%) (mean difference, 4.2%; 95% CI, -3.8% to 12.2%). As a secondary end point, 402 of 817 patients (49.2%) at intervention hospitals received all the therapies that they were eligible for vs 203 of 807 (25.2%) in the control hospitals (odds ratio, 2.59; 95% CI, 1.22–5.53; p = 0.01).

Conclusions and Relevance

A multifaceted quality improvement intervention did not result in a significant increase in composite adherence score for evidence-based therapies in patients with AIS or TIA. However, when using an all-or-none approach, the intervention resulted in improved adherence to evidence-based therapies.

Trial Registration

ClinicalTrials.gov identifier: NCT02223273.

---

### Tratamiento e intervención para accidentes… [^117XgfYw]. CDC (2024). Medium credibility.

Tratamiento del accidente cerebrovascular isquémico Si llega al hospital dentro de las 3 horas de haber tenido los primeros síntomas de un accidente cerebrovascular isquémico, es posible que reciba un tipo de medicamento llamado trombolítico que disuelve trombos o coágulos de sangre. El activador tisular del plasminógeno es un trombolítico. El tPA mejora las probabilidades de recuperarse de un accidente cerebrovascular. Hay estudios que muestran que los pacientes con accidente cerebrovascular isquémico que reciben el activador tisular del plasminógeno tienen más probabilidades de recuperarse completamente o de tener menor discapacidad que los pacientes que no reciben el medicamento. Además, los pacientes tratados con tPA también tienen menos probabilidades de necesitar cuidados a largo plazo en un centro para personas de mayor edad.

Reconocer los signos y síntomas y buscar atención médica inmediata es esencial para prevenir la discapacidad o muerte relacionadas con un accidente cerebrovascular. Los médicos podrían también tratar un accidente cerebrovascular isquémico con otros medicamentos, como anticoagulantes, así como con una operación para remover el coágulo. Accidente cerebrovascular isquémico La mayoría de los accidentes cerebrovasculares son isquémicos. Un accidente cerebrovascular isquémico ocurre cuando los coágulos de sangre u otras partículas bloquean los vasos sanguíneos del cerebro. Los depósitos de grasa llamados placa también pueden causar bloqueos al acumularse en los vasos sanguíneos. Tratamiento del accidente cerebrovascular hemorrágico Se podrían necesitar otros medicamentos, operaciones o procedimientos para detener el sangrado causado por un accidente cerebrovascular hemorrágico y para salvar tejido cerebral.

Se podrían necesitar medicamentos, operaciones u otros procedimientos para detener el sangrado y salvar tejido cerebral. Por ejemplo: Procedimientos intravascularesLos procedimientos intravasculares, los cuales pueden ayudar a reparar un punto débil o una ruptura en un vaso sanguíneo, podrían usarse para tratar ciertos accidentes cerebrovasculares hemorrágicos. Infórmese más sobre el procedimiento. Tratamiento quirúrgicoLos accidentes cerebrovasculares hemorrágicos podrían tratarse con una operación. Si el sangrado es causado por la ruptura de un aneurisma, puede que se coloque un clip metálico para detener la pérdida de sangre.

---

### La FDA aprueba el primer sistema de rehabilitación de su… [^116ZNLJF]. FDA (2021). Medium credibility.

La Administración de Alimentos y Medicamentos de los EE. UU. aprobó hoy el sistema MicroTransponder Vivistim Paired VNS, un sistema de rehabilitación sin medicamentos, el primero de su tipo, destinado a tratar los déficits motores de las extremidades superiores de moderados a graves, asociados con el accidente cerebrovascular isquémico crónico, un accidente cerebrovascular causado por una obstrucción del flujo sanguíneo al cerebro con síntomas duraderos, mediante la estimulación del nervio vago. "La aprobación de hoy del sistema Vivistim Paired VNS ofrece la primera opción de rehabilitación del accidente cerebrovascular mediante la estimulación del nervio vago. Utilizado junto con el ejercicio de rehabilitación, este dispositivo puede ofrecer beneficios a aquellos que han perdido la función en sus extremidades superiores debido a un accidente cerebrovascular isquémico".

El sistema Vivistim está indicado para utilizarse, junto con la terapia de rehabilitación posterior al accidente cerebrovascular, en pacientes que han sufrido un accidente cerebrovascular isquémico, para estimular eléctricamente el nervio vago, un nervio que va desde el cerebro hasta el abdomen, con el fin de reducir las deficiencias en la función motora de las extremidades superiores y mejorar la capacidad de los pacientes para mover los brazos y las manos. La eficacia del sistema Vivistim se midió usando la Evaluación de Fugl-Meyer de las Extremidades Superiores, una evaluación específica del deterioro motor en caso de accidente cerebrovascular. El progreso se midió como un aumento en la función motora a partir de la línea de base después de seis semanas de terapia.

El sistema Vivistim no está aprobado para su uso fuera de su uso previsto para estimular el nervio vago durante la terapia de rehabilitación de accidentes cerebrovasculares isquémicos crónicos para la pérdida moderada a grave de la función de las extremidades superiores. No debe utilizarse en pacientes con vagotomía, que es la extirpación quirúrgica de parte del nervio vago. El sistema MicroTransponder Vivistim Paired VNS es fabricado por MicroTransponder Inc.

---

### Activador del plasminógeno tisular recombinado… [^115AQjwW]. NCI (2011). Low credibility.

activador del plasminógeno tisular recombinadoListen to pronunciationForma de activador del plasminógeno tisular que se produce en el laboratorio. Ayuda a disolver los coágulos de sangre y se usa para tratar ataques cardíacos, accidentes cerebrovasculares y coágulos en los pulmones. Asimismo, está en estudio para el tratamiento de cáncer. Es un tipo de trombolítico sistémico. También se llama activador del plasminógeno tisular recombinante, Activase, alteplasa y r-tPA. Consulte el Diccionario de cáncer del NCIEmpieza conContieneNavegar por letra inicial: ABCDEFGHIJKLMNOPQRSTUVWXYZ#